Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1

Digestive and Liver Disease

Volumn 44, Issue 3, 2012, Pages 228-234

  Barbe, Coralie ^a   Murat, Arnaud ^b   Dupas, Benoit ^b   Ruszniewski, Philippe ^c   Tabarin, Antoine ^d   Vullierme, Marie Pierre ^c   Penfornis, Alfred ^e   Rohmer, Vincent ^f   Baudin, Eric ^g   Le Rhun, Marc ^b   Gaye, Delphine ^h   Marcus, Claude ^a   Cadiot, Guillaume ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b HÔTEL DIEU   (France)

^c BEAUJON HOSPITAL   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Malignancy; Pancreatic neuroendocrine tumours; Surgery; Tumour size

Indexed keywords

GADOLINIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SIZE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOSCOPIC ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGIST;

ADOLESCENT; ADULT; AGED; CONTRAST MEDIA; ENDOSONOGRAPHY; FALSE NEGATIVE REACTIONS; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84856586635     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.09.014     Document Type: Article

References (50)

1. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86:5658-5671.
2. Wautot V., Vercherat C., Lespinasse J., et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat 2002, 20:35-47.
3. Chanson P., Cadiot G., Murat A. Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. GENEM 1. Groupe d'Etude des Neoplasies Endocriniennes Multiples de type 1. Horm Res 1997, 47:211-220.
4. Thomas-Marques L., Murat A., Delemer B., et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumours in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006, 101:266-273.
5. Skogseid B., Eriksson B., Lundqvist G., et al. Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 1991, 73:281-287.
6. Ballard H.S., Fame B., Hartsock R.J. Familial multiple endocrine adenoma-peptic ulcer complex. Medicine (Baltimore) 1964, 43:481-516.
7. Vasen H.F., Lamers C.B., Lips C.J. Screening for the multiple endocrine neoplasia syndrome type I. A study of 11 kindreds in The Netherlands. Arch Intern Med 1989, 149:2717-2722.
8. Shepherd J.J. The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized?. Arch Surg 1991, 126:935-952.
9. Goudet P., Murat A., Binquet C., et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010, 34:249-255.
10. Triponez F., Dosseh D., Goudet P., et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumours of the pancreas. Ann Surg 2006, 243:265-272.
11. Cadiot G., Vuagnat A., Doukhan I., et al. Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology 1999, 116:286-293.
12. Burgess J.R., Greenaway T.M., Parameswaran V., et al. Enteropancreatic malignancy associated with multiple endocrine neoplasia type 1: risk factors and pathogenesis. Cancer 1998, 83:428-434.
13. Doherty G.M., Olson J.A., Frisella M.M., et al. Lethality of multiple endocrine neoplasia type I. World J Surg 1998, 22:581-586.
14. Gibril F., Venzon D.J., Ojeaburu J.V., et al. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 2001, 86:5282-5293.
15. Wilkinson S., Teh B.T., Davey K.R., et al. Cause of death in multiple endocrine neoplasia type 1. Arch Surg 1993, 128:683-690.
16. Goudet P., Murat A., Cardot-Bauters C., et al. Thymic neuroendocrine tumours in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg 2009, 33:1197-1207.
17. Falconi M., Plockinger U., Kwekkeboom D.J., et al. Well-differentiated pancreatic nonfunctioning tumours/carcinoma. Neuroendocrinology 2006, 84:196-211.
18. Triponez F., Goudet P., Dosseh D., et al. Is surgery beneficial for MEN1 patients with small (< or =2cm), nonfunctioning pancreaticoduodenal endocrine tumour? An analysis of 65 patients from the GTE. World J Surg 2006, 30:654-662.
19. Norton J.A., Alexander H.R., Fraker D.L., et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001, 234:495-505.
20. Akerstrom G., Hessman O., Skogseid B., et al. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumours of the pancreas in MEN 1. Langenbecks Arch Surg 2002, 386:558-569.
21. Skogseid B. Multiple endocrine neoplasia type 1. Br J Surg 2003, 90:383-385.
22. Bartsch D.K., Fendrich V., Langer P., et al. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2005, 242:757-764.
23. Hausman M.S., Thompson N.W., Gauger P.G., et al. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 2004, 136:1205-1211.
24. You Y.N., Thompson G.B., Young W.F., et al. Pancreatoduodenal surgery in patients with multiple endocrine neoplasia type 1: operative outcomes, long-term function, and quality of life. Surgery 2007, 142:829-836.
25. Tonelli F., Fratini G., Falchetti A., et al. Surgery for gastroenteropancreatic tumours in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med 2005, 257:38-49.
26. Rosch T., Lightdale C.J., Botet J.F., et al. Localization of pancreatic endocrine tumours by endoscopic ultrasonography. N Engl J Med 1992, 326:1721-1726.
27. Ruszniewski P., Amouyal P., Amouyal G., et al. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995, 117:629-635.
28. Zimmer T., Ziegler K., Bader M., et al. Localisation of neuroendocrine tumours of the upper gastrointestinal tract. Gut 1994, 35:471-475.
29. Anderson M.A., Carpenter S., Thompson N.W., et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumours of the pancreas. Am J Gastroenterol 2000, 95:2271-2277.
30. Wamsteker E.J., Gauger P.G., Thompson N.W., et al. EUS detection of pancreatic endocrine tumours in asymptomatic patients with type 1 multiple endocrine neoplasia. Gastrointest Endosc 2003, 58:531-535.
31. Langer P., Kann P.H., Fendrich V., et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumours in patients with multiple endocrine neoplasia type 1. World J Surg 2004, 28:1317-1322.
32. McLean A.M., Fairclough P.D. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab 2005, 19:177-193.
33. Patel K.K., Kim M.K. Neuroendocrine tumours of the pancreas: endoscopic diagnosis. Curr Opin Gastroenterol 2008, 24:638-642.
34. Kann P.H., Balakina E., Ivan D., et al. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 2006, 13:1195-1202.
35. Hellman P., Hennings J., Akerstrom G., et al. Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1. Br J Surg 2005, 92:1508-1512.
36. Hall E.J., Brenner D.J. Cancer risks from diagnostic radiology. Br J Radiol 2008, 81:362-378.
37. Herwick S., Miller F.H., Keppke A.L. MRI of islet cell tumours of the pancreas. AJR Am J Roentgenol 2006, 187:472-480.
38. Noone T.C., Hosey J., Firat Z., et al. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 2005, 19:195-211.
39. Thoeni R.F., Mueller-Lisse U.G., Chan R., et al. Detection of small, functional islet cell tumours in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 2000, 214:483-490.
40. Ichikawa T., Peterson M.S., Federle M.P., et al. Islet cell tumour of the pancreas: biphasic CT versus MR imaging in tumour detection. Radiology 2000, 216:163-171.
41. Owen N.J., Sohaib S.A., Peppercorn P.D., et al. MRI of pancreatic neuroendocrine tumours. Br J Radiol 2001, 74:968-973.
42. Ku Y.M., Shin S.S., Lee C.H., et al. Magnetic resonance imaging of cystic and endocrine pancreatic neoplasms. Top Magn Reson Imag 2009, 20:11-18.
43. Sotoudehmanesh R., Hedayat A., Shirazian N., et al. Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine 2007, 31:238-241.
44. Kann P.H., Ivan D., Pfutzner A., et al. Preoperative diagnosis of insulinoma: low body mass index, young age, and female gender are associated with negative imaging by endoscopic ultrasound. Eur J Endocrinol 2007, 157:209-213.
45. Caramella C., Dromain C., De Baere T., et al. Endocrine pancreatic tumours: which are the most useful MRI sequences?. Eur Radiol 2010, 20:2618-2627.
46. Napoleon B., Alvarez-Sanchez M.V., Gincoul R., et al. Contrast-enhanced harmonic endoscopic ultrasound in solid lesions of the pancreas: results of a pilot study. Endoscopy 2010, 42:564-570.
47. Ishikawa T., Itoh A., Kawashima H., et al. Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumours. Gastrointest Endosc 2010, 71:951-959.
48. WHO: WHO classification of tumours Pathology and genetics of endocrine organs 2004, IARC Press, Lyon.
49. Rindi G., Kloppel G., Alhman H., et al. TNM staging of foregut (neuro)endocrine tumours: a consensus proposal including a grading system. Virchows Arch 2006, 449:395-401.
50. Kann P.H., Kann B., Fassbender W.J., et al. Small neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumour diameter as determined by endoscopic ultrasound (EUS) imaging. Exp Clin Endocrinol Diabetes 2006, 114:361-365.